editor
progress
multifoc
leukoencephalopathi
pml
caus
human
neurotroph
polyomaviru
jcv
central
nervou
system
cn
diseas
immunodefici
patient
pml
associ
poor
prognosi
intervent
lead
clearanc
viru
remov
iatrogen
immun
suppress
particular
prognosi
dismal
patient
sever
primari
immunodefici
pid
howev
clinic
experi
describ
case
report
support
possibl
nitazoxanid
broadspectrum
antiparasit
antivir
drug
may
help
control
jcv
singl
patient
pml
associ
combin
pid
antivir
effect
nitazoxanid
may
produc
induct
innat
immun
downregul
viral
receptor
interfer
matur
viral
protein
femal
patient
suffer
psychomotor
retard
bilater
optic
nerv
atrophi
refract
amblyopia
due
untreat
hyperopia
develop
lymphopenia
l
refer
rang
ref
l
adolesc
despit
normal
count
l
ref
l
b
cell
matur
defect
margin
zone
l
ref
switch
memori
b
cell
l
ref
respons
pneumococcu
antigen
low
concentr
iga
gl
igg
gl
ige
igm
undetect
cell
count
l
ref
l
cell
l
ref
l
reduc
ratio
p
e
r
c
e
n
g
e
f
r
e
c
e
n
h
c
e
g
r
n
cell
l
ref
low
cell
respond
poorli
concanavalin
phytohaemagglutinin
pokewe
mitogen
percentag
doubl
neg
cell
natur
killer
cell
count
l
ref
l
normal
find
suggest
diagnosi
combin
primari
immunodefici
molecular
karyotyp
found
delet
whole
exom
sequenc
we
patient
parent
unaffect
brother
dna
fail
find
known
condit
parent
origin
restrict
geograph
region
degre
consanguin
seen
we
sinc
age
suffer
chronic
skin
ulcer
granulomat
histolog
receiv
numer
empir
treatment
bacteria
mycobacteria
fungi
supplementari
data
skin
sampl
found
posit
rubella
viru
rv
vaccin
strain
ra
age
patient
perelygina
l
et
al
day
posit
jcv
find
mark
day
case
descript
day
experiment
treatment
rv
start
weekli
dose
three
week
follow
dose
reduct
due
dizzi
associ
inject
sevenweek
treatment
fail
improv
condit
skin
lesion
age
epilepsi
poorli
control
valproat
levetiracetam
pregabalin
oxcarbazepin
monotherapi
combin
attempt
supplement
data
addit
exhibit
subacut
deterior
mild
hemiparesi
suffer
slur
speech
sinc
day
continu
slow
progress
neurolog
condit
sevenweek
treatment
day
day
whether
caus
immun
reconstitut
resist
therapi
remain
open
debat
day
brain
magnet
reson
imag
mri
reveal
somewhat
atyp
pattern
lesion
pml
supplement
data
csf
found
posit
jcv
dna
copiesml
csf
neg
rv
human
herpesviru
enterovirus
herp
simplex
varicella
zoster
cryptococci
toxoplasma
sign
bacteria
mycobacteria
fungi
cn
lymphoma
found
addit
diagnosi
pml
patient
continu
suffer
rvposit
skin
ulcer
base
known
broad
antivir
activ
start
receiv
oral
nitazoxanid
mg
twice
daili
day
attempt
treat
pml
rv
singl
oral
dose
nitazoxanid
report
produc
peak
plasma
concentr
human
rubella
influenza
coronaviru
hepat
c
day
acut
ex
vivo
interferon
gamma
tumor
necrosi
factor
alpha
secret
cell
upon
jcv
peptid
stimul
normal
compar
two
natalizumabassoci
fig
contrast
jcvspecif
cell
respons
absent
cell
collect
month
pml
diagnosi
compar
six
healthi
individu
cell
secret
month
pml
diagnosi
indic
prior
exposur
jcv
fig
hcpre
reaction
polyclon
phorbol
pma
averag
cell
averag
cell
fig
ratio
reduc
month
prior
pml
diagnosi
restor
valu
five
week
start
nitazoxanid
indic
cell
expans
obviou
improv
chronic
wound
observ
although
rv
elimin
lesion
nitazoxanid
treatment
atyp
lesion
continu
fluctuat
followup
brain
mri
supplement
data
day
csf
still
posit
jcv
dna
viral
load
drop
level
accur
quantit
thu
nitazoxanid
treatment
continu
without
obviou
side
effect
total
day
day
day
csf
neg
jcv
dna
obviou
clinic
progress
neurolog
symptom
although
suffer
episod
aspir
pneumonia
febril
urinari
tract
infect
sadli
develop
anoth
episod
aspir
pneumonia
lead
death
day
summari
patient
develop
mild
hemiparesi
slur
speech
treatment
therapi
slow
progress
neurolog
symptom
observ
similar
interferon
treatment
attempt
jcv
pml
also
ineffect
previous
report
pid
case
howev
seem
like
nitazoxanid
may
influenc
cours
pml
patient
indic
enhanc
jcvspecif
cell
respons
subsequ
clearanc
jcv
dna
prolong
clinic
stabl
period
without
obviou
progress
pml
intervent
control
jcv
attempt
immunosuppress
medic
use
discontinu
patient
blood
count
care
monitor
throughout
treatment
far
awar
revers
csf
jcv
nucleic
acid
undetect
level
clinic
pml
pid
patient
rare
ever
previous
report
conclud
potenti
nitazoxanid
explor
larger
pml
patient
popul
suffer
primari
immunodefici
emphas
howev
molecular
basi
pid
patient
understood
describ
experi
may
necessarili
reproduc
pid
patient
jcv
peptid
pool
assay
miltenyi
biotec
bergisch
gladbach
germani
perform
accord
manufactur
instruct
brief
thaw
peripher
blood
mononuclear
cell
either
rest
neg
control
stimul
stock
solut
stimul
pma
ionomycin
pma
six
hour
addit
brefeldin
two
hour
harvest
cell
stain
fluorochromeconjug
antibodi
fixat
permeabil
intracellularli
stain
anti
biolegend
san
diego
usa
previous
describ
stimul
calcul
subtract
neg
control
valu
valu
